Comparison of Spot versus Long Stenting for Femoropopliteal Artery Disease

PARADE Investigators

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Optimal stenting strategy for long femoropopliteal artery lesions still remains undefined. Longer stent length has been shown to be associated with increased risk of restenosis. We sought to compare the efficacy of spot versus long stenting in the treatment of femoropopliteal artery disease. Methods: This study was designed as a multicenter randomized controlled trial to compare immediate and mid-term outcomes of spot versus long primary stenting for femoropopliteal arterial lesions. A total of 125 patients were randomized 1:1 to spot stenting group (n = 59) or long stenting group (n = 66). Results: All lesions were treated with self-expanding bare nitinol stents. Baseline clinical and lesion characteristics were similar between the 2 groups except for male gender and current smoker. The mean lesion length was 24.1 ± 8.8 cm. Technical success was achieved in all patients. The 1-year primary patency and TLR-free (target lesion revascularization) survival did not differ significantly between the 2 groups. However, the spot stenting group showed a trend toward higher primary patency (86.1% vs. 72.7%, P = 0.158) and TLR-free survival (94.2% vs. 82.5%, P = 0.120). The total stented length (hazard ratio [HR] 1.01, 95% confidence interval [CI] 1.00–1.01, P = 0.011) and age (HR 0.94, 95% CI 0.90–1.00, P = 0.035) were independent predictors of restenosis. Conclusions: The spot stenting appears to be more favorable than the long stenting in terms of primary patency and TLR-free survival, although the difference was not statistically significant. The stented length was an independent predictor of restenosis.

Original languageEnglish
Pages (from-to)101-107
Number of pages7
JournalAnnals of Vascular Surgery
Volume58
DOIs
StatePublished - 1 Jul 2019

Fingerprint

Arteries
Stents
Survival
Confidence Intervals
Randomized Controlled Trials
Therapeutics
nitinol

Cite this

@article{4d24c6136c7b483a87fa301c7f692b8b,
title = "Comparison of Spot versus Long Stenting for Femoropopliteal Artery Disease",
abstract = "Background: Optimal stenting strategy for long femoropopliteal artery lesions still remains undefined. Longer stent length has been shown to be associated with increased risk of restenosis. We sought to compare the efficacy of spot versus long stenting in the treatment of femoropopliteal artery disease. Methods: This study was designed as a multicenter randomized controlled trial to compare immediate and mid-term outcomes of spot versus long primary stenting for femoropopliteal arterial lesions. A total of 125 patients were randomized 1:1 to spot stenting group (n = 59) or long stenting group (n = 66). Results: All lesions were treated with self-expanding bare nitinol stents. Baseline clinical and lesion characteristics were similar between the 2 groups except for male gender and current smoker. The mean lesion length was 24.1 ± 8.8 cm. Technical success was achieved in all patients. The 1-year primary patency and TLR-free (target lesion revascularization) survival did not differ significantly between the 2 groups. However, the spot stenting group showed a trend toward higher primary patency (86.1{\%} vs. 72.7{\%}, P = 0.158) and TLR-free survival (94.2{\%} vs. 82.5{\%}, P = 0.120). The total stented length (hazard ratio [HR] 1.01, 95{\%} confidence interval [CI] 1.00–1.01, P = 0.011) and age (HR 0.94, 95{\%} CI 0.90–1.00, P = 0.035) were independent predictors of restenosis. Conclusions: The spot stenting appears to be more favorable than the long stenting in terms of primary patency and TLR-free survival, although the difference was not statistically significant. The stented length was an independent predictor of restenosis.",
author = "{PARADE Investigators} and Ko, {Young Guk} and Ahn, {Chul Min} and Rha, {Seung Woon} and Yu, {Cheol Woong} and Park, {Sang Ho} and Lee, {Seung Jin} and Lee, {Jae Hwan} and Her, {Sung Ho} and Kang, {Woong Chol} and Cho, {Young Seok} and Seo, {Jae Bin} and Cho, {Yun Hyeong} and Cho, {Young Seok}",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.avsg.2018.11.023",
language = "English",
volume = "58",
pages = "101--107",
journal = "Annals of Vascular Surgery",
issn = "0890-5096",
publisher = "Elsevier Inc.",

}

Comparison of Spot versus Long Stenting for Femoropopliteal Artery Disease. / PARADE Investigators.

In: Annals of Vascular Surgery, Vol. 58, 01.07.2019, p. 101-107.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Comparison of Spot versus Long Stenting for Femoropopliteal Artery Disease

AU - PARADE Investigators

AU - Ko, Young Guk

AU - Ahn, Chul Min

AU - Rha, Seung Woon

AU - Yu, Cheol Woong

AU - Park, Sang Ho

AU - Lee, Seung Jin

AU - Lee, Jae Hwan

AU - Her, Sung Ho

AU - Kang, Woong Chol

AU - Cho, Young Seok

AU - Seo, Jae Bin

AU - Cho, Yun Hyeong

AU - Cho, Young Seok

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: Optimal stenting strategy for long femoropopliteal artery lesions still remains undefined. Longer stent length has been shown to be associated with increased risk of restenosis. We sought to compare the efficacy of spot versus long stenting in the treatment of femoropopliteal artery disease. Methods: This study was designed as a multicenter randomized controlled trial to compare immediate and mid-term outcomes of spot versus long primary stenting for femoropopliteal arterial lesions. A total of 125 patients were randomized 1:1 to spot stenting group (n = 59) or long stenting group (n = 66). Results: All lesions were treated with self-expanding bare nitinol stents. Baseline clinical and lesion characteristics were similar between the 2 groups except for male gender and current smoker. The mean lesion length was 24.1 ± 8.8 cm. Technical success was achieved in all patients. The 1-year primary patency and TLR-free (target lesion revascularization) survival did not differ significantly between the 2 groups. However, the spot stenting group showed a trend toward higher primary patency (86.1% vs. 72.7%, P = 0.158) and TLR-free survival (94.2% vs. 82.5%, P = 0.120). The total stented length (hazard ratio [HR] 1.01, 95% confidence interval [CI] 1.00–1.01, P = 0.011) and age (HR 0.94, 95% CI 0.90–1.00, P = 0.035) were independent predictors of restenosis. Conclusions: The spot stenting appears to be more favorable than the long stenting in terms of primary patency and TLR-free survival, although the difference was not statistically significant. The stented length was an independent predictor of restenosis.

AB - Background: Optimal stenting strategy for long femoropopliteal artery lesions still remains undefined. Longer stent length has been shown to be associated with increased risk of restenosis. We sought to compare the efficacy of spot versus long stenting in the treatment of femoropopliteal artery disease. Methods: This study was designed as a multicenter randomized controlled trial to compare immediate and mid-term outcomes of spot versus long primary stenting for femoropopliteal arterial lesions. A total of 125 patients were randomized 1:1 to spot stenting group (n = 59) or long stenting group (n = 66). Results: All lesions were treated with self-expanding bare nitinol stents. Baseline clinical and lesion characteristics were similar between the 2 groups except for male gender and current smoker. The mean lesion length was 24.1 ± 8.8 cm. Technical success was achieved in all patients. The 1-year primary patency and TLR-free (target lesion revascularization) survival did not differ significantly between the 2 groups. However, the spot stenting group showed a trend toward higher primary patency (86.1% vs. 72.7%, P = 0.158) and TLR-free survival (94.2% vs. 82.5%, P = 0.120). The total stented length (hazard ratio [HR] 1.01, 95% confidence interval [CI] 1.00–1.01, P = 0.011) and age (HR 0.94, 95% CI 0.90–1.00, P = 0.035) were independent predictors of restenosis. Conclusions: The spot stenting appears to be more favorable than the long stenting in terms of primary patency and TLR-free survival, although the difference was not statistically significant. The stented length was an independent predictor of restenosis.

UR - http://www.scopus.com/inward/record.url?scp=85062694981&partnerID=8YFLogxK

U2 - 10.1016/j.avsg.2018.11.023

DO - 10.1016/j.avsg.2018.11.023

M3 - Article

VL - 58

SP - 101

EP - 107

JO - Annals of Vascular Surgery

JF - Annals of Vascular Surgery

SN - 0890-5096

ER -